HSPB8 and amyotrophic lateral sclerosis: This represents an obvious limitation for the potential use of estrogenic compounds to enhance HSPB8 expression for therapeutic purposes, since their activity, in the specific neuronal population affected in ALS or FLTD, strictly depend on the brain distribution of the ERs, which may jeopardize the protective effects of the drugs.